Abstract:P . vivax malaria is a major global health burden hindering social and economic development throughout many tropical and sub-tropical countries. Pre-erythrocytic (PE) vaccines emerge as an attractive approach for the control and elimination of malaria infection. Therefore, evaluating the magnitude, longevity and prevalence of naturally acquired IgG antibody responses against PE candidate antigens is useful for vaccine design. The antigenicity of five recombinant PE antigens (PvCSP-VK210, PvSSP3, PvM2-MAEBL, PvCelTOS and PvSPECT1) was evaluated in plasma samples from individuals residing in low transmission areas in Thailand (Ranong and Chumphon Provinces). The samples were collected at the time of acute vivax malaria and 90, 270 and 360 days later. The prevalence, magnitude and longevity of total IgG and IgG subclasses were determined for each antigen using the longitudinal data. Our results showed that seropositivity of all tested PE antigens was detected during infection in at least some subjects; anti-PvCSP-VK210 and anti-PvCelTOS antibodies were the most frequent. Titers of these antibodies declined during the year of follow up, but notably seropositivity persisted. Among seropositive subjects at post-infection, high number of subjects possessed antibodies against PvCSP-VK210. Anti-PvSSP3 antibody responses had the longest half-life. IgG subclass profiling showed that the predominant subclasses were IgG1 and IgG3 (cytophilic antibodies), tending to remain detectable for at least 360 days after infection. The present study demonstrated the magnitude and longevity of serological responses to multiple PE antigens of P . vivax after natural infection. This knowledge could contribute to the design of an effective P . vivax vaccine. The main objective of pre-erythrocytic (PE) vaccine development against Plasmodium vivax is to inhibit hepatocyte infection and the development of the hepatic parasite, thus limiting the subsequent invasion of red blood cells. Although immunization with irradiated sporozoites induces immune responses against the circumsporozoite protein (CSP), PE vaccines based on recombinant or synthetic CSP alone have not generated protective immunity. Investigating immune responses to sporozoite proteins which play a key role in PE development could help improve vaccine design strategies. Here, we assessed the prevalence, magnitude and longevity of antibody responses against several PE proteins in vivax malaria patients living in an area of low malaria transmission in Southern Thailand. This study provides evidence that antibody responses to surface, micronemal and traversal proteins of sporozoites developed during acute infection. Although the magnitude of IgG responses to all tested PE antigens declined with time, seropositivity to these antigens was maintained after infection. Future studies demonstrating functional activity of naturally-acquired antibodies against sporozoite invasion of hepatocytes would be invaluable to our understanding of anti-PE immunity and vaccine development.

Longitudinal analysis of antibody responses to Plasmodium vivax sporozoite antigens following natural infection

Development and longevity of naturally acquired antibody and memory B cell responses against Plasmodium vivax infection

Naturally acquired antibodies against Plasmodium vivax pre-erythrocytic stage vaccine antigens inhibit sporozoite invasion of human hepatocytes in vitro

Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies

Dynamics of IgM and IgG Antibody Response Profile against Linear B-Cell Epitopes from Exoerythrocytic (CelTOS and TRAP) and Erythrocytic (CyRPA) Phases of Plasmodium vivax: Follow-Up Study

Longitudinal Analysis of Naturally Acquired PfEMP1 CIDR Domain Variant Antibodies Identifies Associations with Malaria Protection.

Anti-Plasmodium vivax merozoite surface protein 3 Υ (PvMSP3 Υ) antibodies upon natural infection

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin

Naturally Acquired Antibodies Specific for Plasmodium Falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection from Malaria.

Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites

Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b

Plasmodium Falciparum Malaria in the Peruvian Amazon, a Region of Low Transmission, is Associated with Immunologic Memory

Plasmodium Falciparum-Specific IgM B Cells Dominate in Children, Expand with Malaria and Produce Parasite Inhibitory IgM

Plasmodium vivax MSP1-42 kD Variant Proteins Detected Naturally Induced IgG Antibodies in Patients Regardless of the Infecting Parasite Phenotype in Mesoamerica

Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants

Exploring the naturally acquired response to Pvs47 gametocyte antigen

A systematic analysis of the human immune response to Plasmodium vivax

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

An Immunomics Approach for the Analysis of Natural Antibody Responses to Plasmodium Vivax Infection.

Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45